VILLA GUARDIA (COMO), Italy, April 5, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of a symposium, "Advances in the Management of Endothelial Complications of Haematopoietic Stem Cell Transplantation: the Emerging Role of Defibrotide," on April 3, 2011 at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation in Paris.
